Medical beauty company Aestura Corporation (CEO Lim Woonsup) is selling off its filler brand Cleviel.
Amorepacific Group affiliate Aestura Corporation has signed an MOU with biopharmaceutical enterprise Pharma Research Products Co., Ltd. (CEO Jung Sangsoo, Ahn Wonjun) in an agreement to transfer Cleviel on January 11. The formal agreement, which is scheduled to be concluded by February 2018, involves selling its business rights and related technology to Pharma Research Products.
Aestura Corporation, a medical beauty company with a mission to deliver healthy beauty, has core business purposes that are focused on both aesthetic and derma cosmetics. The company’s major businesses include cosmetics brand Aestura and filler brand Cleviel.
As part of Amorepacific Group’s future plans, it aims to focus its resources towards the competitive medical beauty sector including derma cosmetics, and continue to invest in and foster Aestura as a pioneer in the global medical beauty industry.
Aestura aims to be successful in its mission to provide innovative beauty solutions to its customers through medical and clinical channels, and continues to carry its vision of becoming the “hidden champion of medical beauty in Asia,” using all of their available skills and competencies.